Canadian Active & Maintenance Modified Pentasa Study
Status:
Completed
Trial end date:
2011-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to demonstrate that the new modified oral extended-release
Pentasa® 500mg tablet is at least as efficacious as the currently marketed Pentasa® 500mg
tablet in active mild to moderate Ulcerative Colitis (UC) and also in maintenance of
quiescent disease.